Positron Corporation's Joint Venture Submits FDA 510(k) For Its Attrius™ PET Scanner

Main Category: MRI / PET / Ultrasound
Article Date: 29 Jan 2009 - 6:00 PDT

email to a friend   printer friendly   opinions  

Positron Corporation (OTCBB:POSC), a Cardiac Molecular Imaging Solutions Company, announced today that the United States Food and Drug Administration (FDA) has received 510(k) submission for the Company's jointly developed Attrius™ Positron Emission Tomography (PET) scanner product line. This is the first in a series of nuclear imaging products Positron plans to develop through its joint venture Neusoft Positron Medical Systems, based in Shenyang, China. Positron's Attrius™ is a cardiac specific PET only device that competes with other cardiac imaging modalities with its superior quantification capabilities and disease management software all at an attractive price point.

Joseph Oliverio, President of Positron states that "This 510(k) submission is a significant milestone for Positron. Through our joint venture Neusoft Positron Medical Systems we have developed a state of the PET scanner in the Attrius™ that adds great value to our company and our nuclear cardiology product solutions." Oliverio also stated, "The industry has seen an increasing market demand for cardiac PET. This increase stems from favourable reimbursement compared to other imaging modalities combined with its improved diagnostic accuracy. Positron's Attrius™ PET scanner is the solution that thousands of cardiology groups are looking for to improve their bottom line, reduce healthcare costs and provide patients with a superior diagnosis of coronary artery disease. We believe that we can meet and expand the existing market demand with the Attrius™."

About Positron

Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers world's first robotic systems (Nuclear Pharm-Assis® & Cardio-Assist™) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius™) and SPECT cameras (Pulse®);. Positron's SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.

Forward Looking Statements

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

Positron Corporation

• Additional
• References
• Citations